1
|
Perry R, Forshaw A, Childs J, Chester D, Edwards C. Cultivating Competency in Cardiac Sonography: Aligning Entrustable Professional Activities With Industry Expectations. Heart Lung Circ 2024:S1443-9506(24)00060-X. [PMID: 38458932 DOI: 10.1016/j.hlc.2024.01.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2023] [Revised: 01/17/2024] [Accepted: 01/18/2024] [Indexed: 03/10/2024]
Abstract
BACKGROUND & AIM Echocardiography education involves the teaching and assessment of multiple competencies to ensure work-ready graduates. To connect these competency standards to professional practice, it is important that the industry expectation around specific entrustable professional activities (EPAs) is determined. In Australia, echocardiography examinations are eligible for Medicare reimbursement when performed by sonographers listed on the Australian Sonographers Accreditation Registry (ASAR), either as an Accredited Medical Sonographer or as an Accredited Student Sonographer. A key criterion for acceptance onto the registry is the completion of, or active enrolment in, an accredited cardiac sonography course. Eligible courses apply for accreditation and are assessed by ASAR against their Standards for Accreditation of Sonographer Courses. This study sought to investigate the existing cardiac EPAs and provide insights into the industry's expectations for graduate cardiac sonographers in Australia. METHODS Using an anonymous online survey tool, an invitation to participate was circulated via professional sonography groups and social media platforms. Accredited Medical Sonographers, Accredited Student Sonographers or interested stakeholders (academic, employer, medical specialist) working in Australia or New Zealand were invited to complete the survey. Survey questions were structured around the existing EPAs and knowledge items described in published sonography competency documents. Participants were asked if each individual EPA should be considered appropriate at the threshold of graduation, or at a higher level following a period of working in the profession. RESULTS There were 211 cardiac sonographers who completed the survey. The majority of respondents (148 of 211, 72.2%) indicated that the current EPAs should be updated. At 80% agreement, the following EPAs were considered essential for the graduate: left ventricular structure and function, right ventricular structure and function, atrial size, valvular disease, systemic hypertension, cardiomyopathies, diseases of the aorta, coronary artery disease, pulmonic hypertension, and basic congenital heart disease. This list is more extensive than the current ASAR-endorsed EPAs, and the findings in this research will guide the revision of current ASAR-endorsed EPAs for graduate-level cardiac sonography. CONCLUSIONS The results of this study show Accredited Medical Sonographers completing a cardiac sonography course in Australia should be entrusted to perform a wide range of examinations however, greater alignment between educational providers, ASAR and industry is still required.
Collapse
Affiliation(s)
- Rebecca Perry
- Allied Health and Human Performance, University of South Australia, Adelaide, SA, Australia.
| | - Anthony Forshaw
- School of Clinical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Qld, Australia
| | - Jessie Childs
- Allied Health and Human Performance, University of South Australia, Adelaide, SA, Australia
| | - Deanne Chester
- School of Health, Medical and Applied Sciences, Central Queensland University, Brisbane, Qld, Australia
| | - Christopher Edwards
- School of Clinical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Qld, Australia
| |
Collapse
|
2
|
Smart L, Pelentsov L, Childs J, Williams N, Esterman A. Nurses assessment of development hip dysplasia: A scoping review. J Child Health Care 2024; 28:132-149. [PMID: 35670703 DOI: 10.1177/13674935221095647] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Developmental hip dysplasia is an abnormality of the hip joint which is associated with an unstable or dislocatable hip. During infancy, hips should be screened to determine whether they are stable, unstable or dislocated. In Australia, this screening is often performed by nurses using physical assessment. Physical examination includes a number of assessments which seek to identify underlying abnormalities in hip joint anatomy and function. This scoping review outlines the physical assessments used by nurses in the screening and surveillance of developmental hip dysplasia. A review of the literature identified 15 (N = 15; 100%) sources of evidence, which included original research articles (n = 6; 40%), expert opinion pieces (n = 2; 13.3%) and practice guidelines (n = 7; 46.7%). There were 18 physical assessments identified as being used by nurses in the screening process for developmental hip dysplasia. However, it is apparent that high quality research is required to examine the timing, specificity and sensitivity of the physical assessments identified.
Collapse
Affiliation(s)
- Larissa Smart
- School of Nursing, University of Tasmania, Burnie, TAS, Australia
- Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia
| | - Lemuel Pelentsov
- Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia
| | - Jessie Childs
- Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia
| | - Nicole Williams
- Department of Orthopaedic Surgery, Women's and Children's Hospital, North Adelaide, SA, Australia
| | - Adrian Esterman
- Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia
| |
Collapse
|
3
|
Edwards C, Perry R, Chester D, Childs J. Entrustable professional activities of graduate accredited General Medical Sonographers in Australia - Industry perceptions. J Med Radiat Sci 2023; 70:229-238. [PMID: 37029950 PMCID: PMC10500106 DOI: 10.1002/jmrs.676] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2023] [Accepted: 03/20/2023] [Indexed: 04/09/2023] Open
Abstract
INTRODUCTION Linking individual competencies to entrustable professional tasks provides a holistic view of Sonography graduate work readiness. The Australian Sonographers Accreditation Registry (ASAR) publishes a set of entrustable professional activities (EPAs) as part of its Standards for Accreditation of Sonography Courses. EPAs are distinct ultrasound examinations grouped within six critical practice units. This study reports on industry perspectives of current EPAs and their classification for graduates completing general sonography courses in Australia. The article also examines the value of EPAs and links their function to the assessment of graduate competency. METHODS An online survey tool elicited stakeholder feedback on graduate EPAs across six critical practice units and the potential for including a new Paediatric unit. From an original sample size of 655, 309 responded to questions about general sonography courses. RESULTS A majority (55.3%) recommended no changes to the existing EPA list, and 44.7% recommended amending the list. From respondents that recommended changes (138/309), all current EPAs received >80% agreement to be retained; in addition, nine new examinations received >70% agreement for inclusion at the graduate level. Whilst 42.7% (132/309) supported the current ASAR model requiring competency in five out of six critical practice units, 45.6% (141/309) recommended increasing it to all six. There was limited support, 11.7% (36/309), to reduce this number. Responding to the potential to add a new Paediatric specific critical practice unit, 61.8% (181/293) recommended its inclusion. CONCLUSIONS The findings demonstrate that the current list of EPAs aligns with industry expectations. In contrast, there are divergent views on the modelling and grouping of critical practice units. The article's critical analysis of the results and implications provides stakeholders with a practical approach to clinical teaching and EPA assessment, and helps to inform any review of accreditation standards.
Collapse
Affiliation(s)
- Christopher Edwards
- School of Clinical Sciences, Faculty of HealthQueensland University of TechnologyBrisbaneQueenslandAustralia
| | - Rebecca Perry
- Allied Health and Human PerformanceUniversity of South AustraliaAdelaideSouth AustraliaAustralia
| | - Deanne Chester
- School of Health, Medical and Applied SciencesCentral Queensland UniversityBrisbaneQueenslandAustralia
| | - Jessie Childs
- Allied Health and Human PerformanceUniversity of South AustraliaAdelaideSouth AustraliaAustralia
| |
Collapse
|
4
|
Hill K, Jaensch A, Childs J, McDonald S. Evaluation of point of care ultrasound (POCUS) training on arteriovenous access assessment and cannula placement for haemodialysis. J Vasc Access 2023:11297298231194100. [PMID: 37622472 DOI: 10.1177/11297298231194100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/26/2023] Open
Abstract
BACKGROUND Haemodialysis requires a permanent vascular access and relies on cannulation with two large bore needles. Point Of Care Ultrasound (POCUS) is a tool that may assist nursing staff with visualising cannula placement and prevent miscannulation. This can be particularly useful in regional hospitals with limited access to vascular access specialists. AIMS To examine the impact of POCUS provision and education for nursing staff on confidence in cannulation and to understand the patient experience at three regional hospital haemodialysis units in South Australia. METHODS A POCUS machine and dedicated nursing education were provided at each of the three sites. A pre-test post-test model was used to assess the individual nurses perceived competency before and after the delivery of a series of online ultrasound education modules and face to face training. Patient reported outcome measures (PROMs) were collected to understand the use of POCUS from the client perspective. RESULTS There was a shift towards 'agree' or 'strongly agree' for all nursing surveys in regard to perceived competency (n = 15). This was statistically significant (p ⩽ 0.05) for all questions other than question 1 'I am confident in my ability to physically assess vascular access' (p = 0.06). The patients that completed the PROMs (n = 17) overall supported the ease and use of POCUS for haemodialysis cannulation and felt that it contributed to the nursing staff competency in cannulation. CONCLUSION POCUS has the potential to be a valuable tool in regional haemodialysis units to support vascular access cannulation and potentially avoid metropolitan transfer due to cannulation difficulties. The non-significant change post intervention for question 1 likely reflects the haemodialysis nurses inherent pre-existing capacity to assess vascular access without the use of POCUS using the standard process of visual inspection, the use of a stethoscope and palpation ('look, listen and feel').
Collapse
Affiliation(s)
- Kathleen Hill
- University of South Australia, Adelaide, SA, Australia
| | | | - Jessie Childs
- University of South Australia, Adelaide, SA, Australia
| | | |
Collapse
|
5
|
Cohen C, Pignata S, Bezak E, Tie M, Childs J. Workplace interventions to improve well-being and reduce burnout for nurses, physicians and allied healthcare professionals: a systematic review. BMJ Open 2023; 13:e071203. [PMID: 37385740 PMCID: PMC10314589 DOI: 10.1136/bmjopen-2022-071203] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/19/2022] [Accepted: 05/23/2023] [Indexed: 07/01/2023] Open
Abstract
There is a growing need for interventions to improve well-being in healthcare workers, particularly since the onset of COVID-19. OBJECTIVES To synthesise evidence since 2015 on the impact of interventions designed to address well-being and burnout in physicians, nurses and allied healthcare professionals. DESIGN Systematic literature review. DATA SOURCES Medline, Embase, Emcare, CINAHL, PsycInfo and Google Scholar were searched in May-October 2022. ELIGIBILITY CRITERIA FOR SELECTING STUDIES Studies that primarily investigated burnout and/or well-being and reported quantifiable preintervention and postintervention outcomes using validated well-being measures were included. DATA EXTRACTION AND SYNTHESIS Full-text articles in English were independently screened and quality assessed by two researchers using the Medical Education Research Study Quality Instrument. Results were synthesised and presented in both quantitative and narrative formats. Meta-analysis was not possible due to variations in study designs and outcomes. RESULTS A total of 1663 articles were screened for eligibility, with 33 meeting inclusion criterium. Thirty studies used individually focused interventions, while three were organisationally focused. Thirty-one studies used secondary level interventions (managed stress in individuals) and two were primary level (eliminated stress causes). Mindfulness-based practices were adopted in 20 studies; the remainder used meditation, yoga and acupuncture. Other interventions promoted a positive mindset (gratitude journaling, choirs, coaching) while organisational interventions centred on workload reduction, job crafting and peer networks. Effective outcomes were reported in 29 studies, with significant improvements in well-being, work engagement, quality of life and resilience, and reductions in burnout, perceived stress, anxiety and depression. CONCLUSION The review found that interventions benefitted healthcare workers by increasing well-being, engagement and resilience, and reducing burnout. It is noted that the outcomes of numerous studies were impacted by design limitations that is, no control/waitlist control, and/or no post intervention follow-up. Suggestions are made for future research.
Collapse
Affiliation(s)
- Catherine Cohen
- Allied Health and Human Performance, University of South Australia, Adelaide, South Australia, Australia
| | - Silvia Pignata
- STEM, University of South Australia, Adelaide, South Australia, Australia
| | - Eva Bezak
- Allied Health and Human Performance, University of South Australia, Adelaide, South Australia, Australia
| | - Mark Tie
- Australian Radiology Clinics, Adelaide, South Australia, Australia
| | - Jessie Childs
- Allied Health and Human Performance, University of South Australia, Adelaide, South Australia, Australia
| |
Collapse
|
6
|
Cormack CJ, Childs J, Kent F. Point-of-Care Ultrasound Educational Development in Australasia: A Scoping Review. Ultrasound Med Biol 2023; 49:1375-1384. [PMID: 36941181 DOI: 10.1016/j.ultrasmedbio.2023.02.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/24/2022] [Revised: 01/12/2023] [Accepted: 02/16/2023] [Indexed: 05/11/2023]
Abstract
Point-of-care ultrasound (PoCUS) technology is evolving rapidly and is being adopted by many health professionals in their clinical practice. Ultrasound is a complex skill requiring dedicated training. Appropriate integration of ultrasound education into medical, surgical, nursing and allied health professions is a current challenge worldwide. There are patient safety implications for use of ultrasound without adequate training and frameworks. The purpose of the review was to overview the status of PoCUS education in Australasia; investigate what is being taught and learned about ultrasound across the health professions; and identify potential gaps. The review was limited to postgraduate and qualified health professionals with established or emerging clinical use for PoCUS. A scoping review methodology was used to include literature in peer-reviewed articles, policies, guidelines, position statements, curricula and online material relating to ultrasound education. One hundred thirty-six documents were included. The literature revealed heterogeneity in ultrasound teaching and learning across the health professions. Several health professions lacked any defined scopes of practice, policies or curricula. Significant investment in resourcing ultrasound education is required to address the current needs in Australia and New Zealand.
Collapse
Affiliation(s)
- Carolynne J Cormack
- Monash University, Faculty of Medicine Nursing and Health Sciences, Victoria, Australia; Monash Health, Department of Medical Imaging, Victoria, Australia.
| | - Jessie Childs
- Faculty of Allied Health and Human Performance, University of South Australia, Adelaide, Australia
| | - Fiona Kent
- Monash University, Faculty of Medicine Nursing and Health Sciences, Victoria, Australia
| |
Collapse
|
7
|
Guscott A, Deslandes A, Parange N, Childs J. Australasian sonographers' knowledge, awareness, and attitudes towards the international evidence-based guidelines for the diagnosis of polycystic ovarian syndrome. Australas J Ultrasound Med 2023; 26:34-45. [PMID: 36960132 PMCID: PMC10030092 DOI: 10.1002/ajum.12331] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
Introduction/Purpose Many guidelines have been utilised to diagnose polycystic ovarian syndrome (PCOS). The most recent are the International Evidence Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome 2018 (2018 IEBG). This study aimed to assess the awareness, knowledge, and attitudes of Australasian sonographers' regarding these guidelines. Methods An online cross-sectional survey was disseminated to sonographers. Qualitative and quantitative questions were asked around awareness, knowledge, and attitudes towards the 2018 IEBG. Statistical and thematic analyses of the results were performed. Results Ninety responses were included in the final analysis. Fifty-two percent (52.2%) of participants were aware of the 2018 IEBG but only 31.1% used it in their workplaces. Fifty-eight percent (57.9%) of participants correctly identified the sonographic features that suggest PCOS, and 3.5% correctly identified all minimum recommended inclusions for reporting a gynaecological ultrasound for PCOS. Prior to being supplied the 2018 IEBG, 15.8% of participants correctly answered clinical scenario-based knowledge questions, which increased to 29.4% correctly after being supplied the guideline; however, this difference was not statistically significant. There were no statistically significant associations between demographics and knowledge of the 2018 IEBG. Discussion Several areas of confusion surrounding wording and interpretation of the 2018 IEBG were highlighted. Consideration should be given to barriers of implementation and strategies to overcome these. Conclusion More education surrounding the sonographic diagnosis of PCOS and the 2018 IEBG is needed. Scanning protocols used amongst sonographers varied, suggesting that inconsistency in sonographic diagnosis may exist. Future reviews of the 2018 IEBG should focus on reducing ambiguity in wording, which may be responsible for some of the varied interpretation of these guidelines.
Collapse
Affiliation(s)
- Alexandra Guscott
- Allied Health and Human PerformanceUniversity of South AustraliaAdelaideSouth AustraliaAustralia
| | - Alison Deslandes
- Allied Health and Human PerformanceUniversity of South AustraliaAdelaideSouth AustraliaAustralia
| | - Nayana Parange
- Allied Health and Human PerformanceUniversity of South AustraliaAdelaideSouth AustraliaAustralia
| | - Jessie Childs
- Allied Health and Human PerformanceUniversity of South AustraliaAdelaideSouth AustraliaAustralia
| |
Collapse
|
8
|
Edwards C, Thoirs K, Osborne B, Slade D, McDonald S, Lombardo P, Chandler A, Quinton A, Stoodley P, Taylor L, Childs J. Australian sonographer competency—A new framework. Sonography 2022. [DOI: 10.1002/sono.12309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Christopher Edwards
- School of Clinical Sciences, Faculty of Health Queensland University of Technology Brisbane Queensland Australia
| | - Kerry Thoirs
- Allied Health and Human Performance University of South Australia Adelaide South Australia Australia
| | - Brooke Osborne
- Allied Health and Human Performance University of South Australia Adelaide South Australia Australia
| | - Debbie Slade
- Australasian Society for Ultrasound in Medicine Chatswood New South Wales Australia
| | - Sandra McDonald
- Allied Health and Human Performance University of South Australia Adelaide South Australia Australia
- Australasian Society for Ultrasound in Medicine Chatswood New South Wales Australia
| | - Paul Lombardo
- Department of Medical Imaging and Radiation Sciences Monash University Clayton Victoria Australia
| | - Amanda Chandler
- Faculty of Science and Health Charles Sturt University Port Macquarie New South Wales Australia
| | - Ann Quinton
- School of Health, Medical and Applied Sciences Central Queensland University Sydney New South Wales Australia
- Sydney Medical School Nepean The University of Sydney Penrith New South Wales Australia
| | - Paul Stoodley
- Blacktown Clinical School and Research Centre, School of Medicine Western Sydney University Blacktown New South Wales Australia
| | - Lucy Taylor
- The Australian Institute of Healthcare Education St Leonards New South Wales Australia
| | - Jessie Childs
- Allied Health and Human Performance University of South Australia Adelaide South Australia Australia
| |
Collapse
|
9
|
Childs J, Thoirs K, Quinton A, Osborne B, Edwards C, Stoodley P, Lombardo P, McDonald S, Slade D, Chandler A, Taylor L, Long J, Pollard K, Halligan T. Development of a Professional Competency Framework for Australian Sonographers – Perspectives for Developing Competencies Using a Delphi Methodology. Int J Qual Health Care 2022; 34:6551067. [PMID: 35311894 PMCID: PMC9002280 DOI: 10.1093/intqhc/mzac017] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2021] [Revised: 02/22/2022] [Accepted: 03/21/2022] [Indexed: 11/16/2022] Open
Abstract
Background Professional competencies are important for enhancing alignment between the needs of education, industry and health consumers, whilst describing public expectations around health professionals. The development of competency standards for the sonography profession defines the behaviours, skills and knowledge sonographers should demonstrate for each learning and experience level. Objective The objective of this project was to develop a set of professional competency standards for the sonography profession which described in depth the behaviours, skills and knowledge sonographers should demonstrate across multiple learning and experience levels. Methods Representatives of three Australian ultrasound professional associations and seven tertiary institutions involved in entry-level sonographer education in Australia formed a research team (RT). The RT recruited an expert panel that responded to six survey rounds. Using a Delphi methodology, the results and free-text comments from each previous round were fed back to participants in the subsequent survey rounds to achieve a consensus. Results The project developed a professional competency framework for sonographers, which included four major domains: detailed competency standards, sonographer knowledge, sonographer attitudes and a holistic competency matrix [https://doi.org/10.6084/m9.figshare.17148035.v2.] Conclusion The Delphi methodology is an effective way to develop professional competency standards. This paper describes the methods and challenges in developing such standards for sonographers which could be translated to other health professionals.
Collapse
Affiliation(s)
- Jessie Childs
- Lecturer Medical Sonography, Allied Health and Human Performance, University of South Australia, Australia
| | - Kerry Thoirs
- Research Assistant, University of South Australia, Australia
| | - Ann Quinton
- Lecturer, Medical Sonography, Central Queensland University, Queensland, Australia
| | - Brooke Osborne
- Lecturer, Allied Health and Human Performance, University of South Australia, Australia
| | - Christopher Edwards
- Lecturer, Medical Sonography, Queensland University of Technology, Queensland, Australia
| | - Paul Stoodley
- Lecturer, Medical Sonography, University of Western Sydney, New South Wales, Australia
| | - Paul Lombardo
- Lecturer, Medical Sonography, Monash University, Victoria, Australia
| | | | - Debbie Slade
- Australasian Society for Ultrasound in medicine, Australia
| | - Amanda Chandler
- Lecturer, Medical Sonography, Charles Sturt University, New South Wales, Australia
| | - Lucy Taylor
- lecturer, Medical Sonography, Australian institute of Healthcare Education, New South Wales
| | - Jodie Long
- CEO, Australasian Sonographers Association, Victoria, Australia
| | - Karen Pollard
- Lecturer, Medical Sonography, University of Canberra, Australian Capital Territory, Australia
| | - Toni Halligan
- Board Member, Australasian Sonographers Accreditation Registry, Victoria, Australia
| |
Collapse
|
10
|
Childs J, Osborne B, Lamb K, Maranna S, Esterman A. The initial impact of COVID-19 on Australasian sonographers part 3: Sonographer professional, personal, and social wellbeing. Sonography 2021; 8:109-115. [PMID: 34540562 PMCID: PMC8441619 DOI: 10.1002/sono.12264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2021] [Revised: 05/03/2021] [Accepted: 05/05/2021] [Indexed: 11/05/2022]
Abstract
Introduction The wellbeing of front‐line healthcare workers can be impacted during a pandemic. This paper reports the initial impact on the wellbeing of COVID‐19 on Australasian sonographers. Methods An online qualitative and quantitative survey was conducted between March and June 2020 to explore the wellbeing of Australasian sonographers in the early stages of the COVID‐19 pandemic. Results Whilst most sonographers felt supported at work (300/379), those working in public hospitals felt more so than those in private practice. Sonographers in private practice felt more as though their job was at risk and were more likely to consider an alternate source of income. Sonographers felt they were working on the front line and many felt anxious about themselves (74%) or family (78%) contracting COVID‐19 due to their employment. Forty‐one percent of sonographers felt more isolated than normal, with younger age groups (18‐34 years) feeling less like they had enough hobbies or selfcare activities to get them through. Twelve percent of sonographers reported never, or rarely, coping with the juggle of work and home life. Conclusion The initial impact of the COVID‐19 pandemic on the wellbeing of sonographers is evident. Longitudinal data will enable wellbeing to be tracked over time.
Collapse
Affiliation(s)
- Jessie Childs
- Allied Health and Human Performance University of South Australia Adelaide Australia
| | - Brooke Osborne
- Allied Health and Human Performance University of South Australia Adelaide Australia
| | - Kathryn Lamb
- Allied Health and Human Performance University of South Australia Adelaide Australia
| | - Sandhya Maranna
- Allied Health and Human Performance University of South Australia Adelaide Australia
| | - Adrian Esterman
- Department of Nursing University of South Australia Adelaide Australia
| |
Collapse
|
11
|
Childs J, Maranna S, Osborne B, Lamb K, Esterman A. The initial impact of COVID-19 on Australasian sonographers part 2: Changes to sonographic examination protocols and access to personal protective equipment. Sonography 2021; 8:100-108. [PMID: 34540561 PMCID: PMC8441849 DOI: 10.1002/sono.12275] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2021] [Revised: 06/16/2021] [Accepted: 06/17/2021] [Indexed: 11/13/2022]
Abstract
INTRODUCTION COVID-19 brought with it the requirement for healthcare workers to limit community transmission of the virus as much as possible by limiting patient contact and wearing Personal Protective Equipment (PPE). This study aimed to capture the initial adaptations to sonographic examination protocols within ultrasound departments and sonographer access to PPE. METHODS An online survey was used to gather data on sonographer reflections of sonographic examination protocol changes seen in their departments and access to PPE between the 11th of March 2020 and the 14th of June 2020. RESULTS To reduce the time sonographers spent with the patients and hence reduce the risk of exposure to COVID-19, sonographers reported adjustments to sonographic examination protocols including their duration and scheduling. Access to PPE was reported as poor. CONCLUSION Numerous sonographic examination protocol changes were observed within ultrasound departments in Australasia in the initial response to COVID-19. Access to PPE was varied along with sonographer feelings around the impact of these changes.
Collapse
Affiliation(s)
- Jessie Childs
- Allied Health and Human PerformanceUniversity of South AustraliaAdelaideAustralia
| | - Sandhya Maranna
- Allied Health and Human PerformanceUniversity of South AustraliaAdelaideAustralia
| | - Brooke Osborne
- Allied Health and Human PerformanceUniversity of South AustraliaAdelaideAustralia
| | - Kathryn Lamb
- Allied Health and Human PerformanceUniversity of South AustraliaAdelaideAustralia
| | - Adrian Esterman
- Clinical and Health SciencesUniversity of South AustraliaAdelaideAustralia
| |
Collapse
|
12
|
Sharp R, Carr P, Childs J, Scullion A, Young M, Flynn T, Kirker C, Jackson G, Esterman A. Catheter to vein ratio and risk of peripherally inserted central catheter (PICC)-associated thrombosis according to diagnostic group: a retrospective cohort study. BMJ Open 2021; 11:e045895. [PMID: 34226216 PMCID: PMC8258560 DOI: 10.1136/bmjopen-2020-045895] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
OBJECTIVES Determine the effect of the catheter to vein ratio (CVR) on rates of symptomatic thrombosis in individuals with a peripherally inserted central catheter (PICC) and identify the optimal CVR cut-off point according to diagnostic group. DESIGN Retrospective cohort study. SETTING 4 tertiary hospitals in Australia and New Zealand. PARTICIPANTS Adults who had undergone PICC insertion. PRIMARY OUTCOME MEASURE Symptomatic thrombus of the limb in which the PICC was inserted. RESULTS 2438 PICC insertions were included with 39 cases of thrombosis (1.6%; 95% CI 1.14% to 2.19%). Receiver operator characteristic analysis was unable to be performed to determine the optimal CVR overall or according to diagnosis. The association between risk of thrombosis and CVR cut-offs commonly used in clinical practice were analysed. A 45% cut-off (≤45% versus ≥46%) was predictive of thrombosis, with those with a higher ratio having more than twice the risk (relative risk 2.30; 95% CI 1.202 to 4.383; p=0.01). This pattern continued when only those with malignancy were included in the analysis, those with cancer had twice the risk of thrombosis with a CVR greater than 45%. Whereas the 33% CVR cut-off was not associated with statistically significant results overall or in those with malignancy. Neither the 33% or 45% CVR cut-off produced statistically significant results in those with infection or other non-malignant conditions. CONCLUSIONS Adherence to CVR cut-offs are an important component of PICC insertion clinical decision making to reduce the risk of thrombosis. These results suggest that in individuals with cancer, the use of a CVR ≤45% should be considered to minimise risk of thrombosis. Further research is needed to determine the risk of thrombosis according to malignancy type and the optimal CVR for those with a non-malignant diagnosis.
Collapse
Affiliation(s)
- Rebecca Sharp
- Clinical and Health Sciences/Rosemary Bryant AO Research Centre, University of South Australia, Adelaide, South Australia, Australia
| | - Peter Carr
- School of Nursing and Midwifery, National University of Ireland Galway, Galway, Ireland
- Alliance for Vascular Access Teaching and Research (AVATAR), Griffith University, Nathan, Queensland, Australia
| | - Jessie Childs
- Clinical & Health Sciences, University of South Australia, Adelaide, South Australia, Australia
| | - Andrew Scullion
- Vascular Access Team, Calvary Mater Hospital, Newcastle, New South Wales, Australia
| | - Mark Young
- Peri-Operative Services, St Vincent's Hospital Sydney, Sydney, New South Wales, Australia
| | - Tanya Flynn
- Cancer Services, St George Hospital, Sydney, New South Wales, Australia
| | - Carolyn Kirker
- Department of Anaesthesia and Pain Management, Capital and Coast District Health Board, Wellington, New Zealand
| | - Gavin Jackson
- Medical Imaging, Fiona Stanley Hospital, Perth, Western Australia, Australia
| | - Adrian Esterman
- Clinical and Health Sciences/Rosemary Bryant AO Research Centre, University of South Australia, Adelaide, South Australia, Australia
| |
Collapse
|
13
|
Childs J, Lamb K, Osborne B, Maranna S, Esterman A. The initial impact of COVID-19 on Australasian Sonographers Part 1: Changes in scan numbers and sonographer work hours. Sonography 2021; 8:90-99. [PMID: 34226862 PMCID: PMC8242911 DOI: 10.1002/sono.12263] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2021] [Revised: 04/30/2021] [Accepted: 05/03/2021] [Indexed: 11/17/2022]
Abstract
Introduction COVID‐19 has seen a series of lockdowns and suspension on non‐urgent elective surgeries. Subsequently, there was a drop in the number of diagnostic imaging services billed in April, May, 2020. A survey was undertaken from March to June 2020 to determine the initial impact of COVID‐19 on Australasian Sonographers. This article, the first in a 3‐part series presents and discusses the results of this survey pertaining to changes in the number of scans performed, and changes in the working hours of sonographers. The remaining two articles in this series address other initial COVID‐19 impacts on Australasian Sonographers. Methods An online survey was conducted containing questions regarding changes to work hours and examination numbers. Results 444 participants answered the survey. Seventy eight percent of sonographers reported a decrease in the number of examinations being performed in their department A decrease in work hours was reported by 68% of sonographers with almost a quarter of these reporting that they had lost all their hours. A higher percentage of work hours changes were seenin private practices. Many reductions in work hours were reported to be voluntary. Conclusion Scan numbers in ultrasound departments were affected by COVID‐19, as were sonographers' work hours.
Collapse
Affiliation(s)
- Jessie Childs
- Allied Health and Human Performance University of South Australia Adelaide Australia
| | - Kathryn Lamb
- Allied Health and Human Performance University of South Australia Adelaide Australia
| | - Brooke Osborne
- Allied Health and Human Performance University of South Australia Adelaide Australia
| | - Sandhya Maranna
- Allied Health and Human Performance University of South Australia Adelaide Australia
| | | |
Collapse
|
14
|
Affiliation(s)
- Catherine Cohen
- School of Health Sciences University of South Australia Adelaide South Australia Australia
| | - Jessie Childs
- School of Health Sciences University of South Australia Adelaide South Australia Australia
| | - Sandhya Maranna
- School of Health Sciences University of South Australia Adelaide South Australia Australia
| |
Collapse
|
15
|
Hill K, Xu Q, Jaensch A, Esterman A, Le Leu R, Childs J, Juneja R, Jesudason S. "Outcomes of arteriovenous fistulae cannulation in the first 6 weeks of use: A retrospective multicenter observational study". J Vasc Access 2020; 22:726-732. [PMID: 32912057 DOI: 10.1177/1129729820954717] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
BACKGROUND Arteriovenous fistula (AVF) management for haemodialysis (HD) is one of the most challenging aspects of clinical care. A successful cannulation outcome when an AVF or arteriovenous graft (AVG) is used for the first time can be influenced by many factors, including access maturity, staff skill, and patient factors. This study examined AVF/AVG outcomes at initiation of HD across two major metropolitan public hospitals. METHODS Electronic medical records were reviewed to collect data retrospectively for a cohort of all newly commencing ESRD HD starts during 2018 to identify cannulation outcomes in the first 6 weeks. RESULTS Of the 117 patients included, AVG use was low (5%). Twenty-four percent of patients required a surgical intervention to salvage a poorly functioning AVF prior to commencing HD. About 32.5% of the cohort had an uneventful start with all successful cannulations. For the remainder of the cohort the number of treatments with unsuccessful cannulation ranged from 1 to 4 or more. About 36% required a surgical intervention for a poorly functioning AVF after commencing HD. Commencing HD with a CVC is associated with a lower likelihood of subsequent successful cannulation (p < 0.001). CONCLUSION Even in experienced centres, a subset of patients experienced complicated cannulation in the first 6 weeks of HD. Several areas of improvement could be considered for these patients; timely referral for access creation, post-operative surveillance to ensure AVF maturation inclusive of duplex ultrasonography, gentle induction using small gauge needles and low blood flows, and consideration of a single needle HD initiation pathway.
Collapse
Affiliation(s)
- Kathleen Hill
- University of South Australia, Adelaide, South Australia, Australia
| | - Qunyan Xu
- University of South Australia, Adelaide, South Australia, Australia
| | - Ashleigh Jaensch
- Central Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, South Australia, Australia
| | - Adrian Esterman
- University of South Australia, Adelaide, South Australia, Australia
| | - Richard Le Leu
- Central and Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, South Australia, Australia.,Department of Medicine, University of Adelaide, Adelaide, South Australia, Australia
| | - Jessie Childs
- University of South Australia, Adelaide, South Australia, Australia
| | - Rajiv Juneja
- Flinders Medical Centre, Bedford Park, South Australia, Australia
| | - Shilpanjali Jesudason
- Central and Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, South Australia, Australia.,Department of Medicine, University of Adelaide, Adelaide, South Australia, Australia
| |
Collapse
|
16
|
Linehan C, Childs J, Quinton AE, Aziz A. Ultrasound parameters to identify and diagnose carpal tunnel syndrome. A review of the literature. Australas J Ultrasound Med 2020; 23:194-206. [PMID: 34760599 DOI: 10.1002/ajum.12219] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
Numerous works of literature have assessed the use of ultrasound to detect carpal tunnel syndrome, suggesting various techniques and cut-off values. Currently, an effective parameter and cut-off value are still debated. The aim of this review is to determine if these parameters have sufficient rigour to allow their use in clinical practice. Twenty-one studies using sonographic parameters to identify carpal tunnel syndrome in comparison with electrodiagnostic testing (EDx) were selected for review. Methodological differences were found between studies in the use of EDx criteria, scanning and recruitment protocols, with participant biometrics often not reported. Parameters including the cross-sectional area of the median nerve at the level of the pisiform bone in addition to the wrist-to-forearm difference demonstrated high diagnostic utility for set cut-off values. Doppler techniques and mobility are promising, and further research is required to understand the effectiveness of these techniques.
Collapse
Affiliation(s)
- Callum Linehan
- Medical Imaging Department Ultrasound Mid North Coast Diagnostic Imaging Forster New South Wales Australia
| | - Jessie Childs
- School of Health Sciences University of South Australia Adelaide South Australia Australia
| | - Ann E Quinton
- School of Health Medical and Applied Science Central Queensland University Sydney New South Wales Australia.,Sydney Medical School Nepean University of Sydney Sydney New South Wales Australia
| | - Aamer Aziz
- School of Health Medical and Applied Sciences Central Queensland University Mackay Queensland Australia
| |
Collapse
|
17
|
Carter S, Hill AM, Yandell C, Buckley JD, Tan SY, Rogers GB, Childs J, Matheson M, Lamb K, Ward S, Stanton TR, Fraysse F, Hills AP, Coates AM. Study protocol for a 9-month randomised controlled trial assessing the effects of almonds versus carbohydrate-rich snack foods on weight loss and weight maintenance. BMJ Open 2020; 10:e036542. [PMID: 32690523 PMCID: PMC7371143 DOI: 10.1136/bmjopen-2019-036542] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
INTRODUCTION Epidemiological studies indicate an inverse association between nut consumption and body mass index (BMI). However, clinical trials evaluating the effects of nut consumption compared with a nut-free diet on adiposity have reported mixed findings with some studies reporting greater weight loss and others reporting no weight change. This paper describes the rationale and detailed protocol for a randomised controlled trial assessing whether the inclusion of almonds or carbohydrate-rich snacks in an otherwise nut-free energy-restricted diet will promote weight loss during 3 months of energy restriction and limit weight regain during 6 months of weight maintenance. METHODS AND ANALYSIS One hundred and thirty-four adults aged 25-65 years with a BMI of 27.5-34.9 kg/m2 will be recruited and randomly allocated to either the almond-enriched diet (AED) (15% energy from almonds) or a nut-free control diet (NFD) (15% energy from carbohydrate-rich snack foods). Study snack foods will be provided. Weight loss will be achieved through a 30% energy restriction over 3 months, and weight maintenance will be encouraged for 6 months by increasing overall energy intake by ~120-180 kcal/day (~500-750kJ/day) as required. Food will be self-selected, based on recommendations from the study dietitian. Body composition, resting energy expenditure, total daily energy expenditure (via doubly labelled water), physical activity, appetite regulation, cardiometabolic health, gut microbiome, liver health, inflammatory factors, eating behaviours, mood and personality, functional mobility and pain, quality of life and sleep patterns will be measured throughout the 9-month trial. The effects of intervention on the outcome measures over time will be analysed using random effects mixed models, with treatment (AED or NFD) and time (baseline, 3 months and 9 months) being the between and within factors, respectively in the analysis. ETHICS AND DISSEMINATION Ethics approval was obtained from the University of South Australia Human Research Ethics Committee (201436). Results from this trial will be disseminated through publication in peer-reviewed journals, national and international presentations. TRIAL REGISTRATION NUMBER Australian New Zealand Clinical Trials Registry (ACTRN12618001861246).
Collapse
Affiliation(s)
- Sharayah Carter
- Allied Health and Human Performance, University of South Australia, Adelaide, South Australia, Australia
- Alliance for Research in Exercise, Nutrition and Activity (ARENA), University of South Australia, Adelaide, South Australia, Australia
| | - Alison M Hill
- Alliance for Research in Exercise, Nutrition and Activity (ARENA), University of South Australia, Adelaide, South Australia, Australia
- Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia
| | - Catherine Yandell
- Allied Health and Human Performance, University of South Australia, Adelaide, South Australia, Australia
- Alliance for Research in Exercise, Nutrition and Activity (ARENA), University of South Australia, Adelaide, South Australia, Australia
| | - Jonathan D Buckley
- Allied Health and Human Performance, University of South Australia, Adelaide, South Australia, Australia
- Alliance for Research in Exercise, Nutrition and Activity (ARENA), University of South Australia, Adelaide, South Australia, Australia
| | - Sze-Yen Tan
- Institute for Physical Activity and Nutrition (IPAN), Deakin University, Burwood, Victoria, Australia
| | - Geraint B Rogers
- Microbiome Research, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, South Australia, Australia
- College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia
| | - Jessie Childs
- Allied Health and Human Performance, University of South Australia, Adelaide, South Australia, Australia
| | - Mark Matheson
- Allied Health and Human Performance, University of South Australia, Adelaide, South Australia, Australia
| | - Kate Lamb
- Allied Health and Human Performance, University of South Australia, Adelaide, South Australia, Australia
| | - Susan Ward
- Allied Health and Human Performance, University of South Australia, Adelaide, South Australia, Australia
- Alliance for Research in Exercise, Nutrition and Activity (ARENA), University of South Australia, Adelaide, South Australia, Australia
| | - Tasha R Stanton
- Allied Health and Human Performance, University of South Australia, Adelaide, South Australia, Australia
- IMPlementation And Clinical Translation (IIMPACT), University of South Australia, Adelaide, South Australia, Australia
- Neuroscience Research Australia, Sydney, New South Wales, Australia
| | - Francois Fraysse
- Allied Health and Human Performance, University of South Australia, Adelaide, South Australia, Australia
- Alliance for Research in Exercise, Nutrition and Activity (ARENA), University of South Australia, Adelaide, South Australia, Australia
| | - Andrew P Hills
- School of Health Sciences, College of Health and Medicine, University of Tasmania, Launceston, Tasmania, Australia
| | - Alison M Coates
- Allied Health and Human Performance, University of South Australia, Adelaide, South Australia, Australia
- Alliance for Research in Exercise, Nutrition and Activity (ARENA), University of South Australia, Adelaide, South Australia, Australia
| |
Collapse
|
18
|
Newton K, Quinton A, Childs J. The incidence of Australian private practice sonographers moving patients unassisted and their level of training: A pilot study. Sonography 2020. [DOI: 10.1002/sono.12219] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Kate Newton
- Bachelor of Medical Sonography/Graduate Diploma of Medical SonographyCQUniversity Brisbane Australia
| | - Ann Quinton
- School of Health, Medical and Applied ScienceCentral Queensland University Brisbane Australia
| | - Jessie Childs
- School of Health, Medical and Applied ScienceCentral Queensland University Brisbane Australia
| |
Collapse
|
19
|
Hennig CL, Childs J, Aziz A, Quinton A. The effect of increased maternal body habitus on image quality and ability to identify fetal anomalies at a routine 18‐20‐week morphology ultrasound scan: a narrative review. Sonography 2019. [DOI: 10.1002/sono.12202] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Christina L. Hennig
- Medical ImagingRoyal Brisbane and Women's Hospital Herston Queensland Australia
| | - Jessie Childs
- School of Health SciencesUniversity of South Australia Adelaide Australia
| | - Aamer Aziz
- School of Health, Medical and Applied SciencesCentral Queensland University Mackay Australia
| | - Ann Quinton
- Medical SonographyCentral Queensland University Australia
| |
Collapse
|
20
|
Hill K, Sharp R, Childs J, Esterman A, Le Leu R, Juneja R, Jesudason S. Cannulation practices at haemodialysis initiation via an arteriovenous fistula or arteriovenous graft. J Vasc Access 2019; 21:573-581. [PMID: 31423945 DOI: 10.1177/1129729819869093] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
INTRODUCTION A functioning long-term vascular access is required for haemodialysis therapy; however, establishing this can be challenging in the setting of advanced age and vessels damaged by diabetes. Complications include the inability to insert two needles for the treatment resulting in miscannulation trauma and in some cases insertion of a temporary central venous access device. The broad objective of this review is to define the evidence base regarding cannulation practices in the initiation of haemodialysis via an arteriovenous fistula or an arteriovenous graft. METHODS This review uses the framework recommended by the Joanna Briggs Institute and the process by which papers were included or excluded followed the standard Preferred Reporting Items for Systematic Reviews and Meta-Analyses group approach. A total of 20 primary research studies met the inclusion criteria. RESULTS Cannulation in the 10- to 15-week period rather than delaying past this time frame is associated with the best outcomes. New vascular access given time to mature through single-needle haemodialysis treatments may improve long-term patency. Duplex ultrasound mapping prior to initiation of cannulation supports the clinical decision-making process on timing of and selection of cannulation sites. CONCLUSION Cannulation trauma at the initiation of haemodialysis could potentially be reduced with a strategy of incremental haemodialysis using single-needle treatment supported with duplex ultrasonography assessment to 'map' the vascular access as a guide for clinicians prior to cannulation initiation.
Collapse
Affiliation(s)
- Kathleen Hill
- University of South Australia, Adelaide, SA, Australia
| | - Rebecca Sharp
- University of South Australia, Adelaide, SA, Australia
| | - Jessie Childs
- University of South Australia, Adelaide, SA, Australia
| | | | - Richard Le Leu
- Central and Northern Adelaide Renal and Transplantation Service, Adelaide, SA, Australia
| | - Rajiv Juneja
- Southern Adelaide Local Health Network, Adelaide, SA, Australia
| | - Shilpa Jesudason
- Central and Northern Adelaide Renal and Transplantation Service, Adelaide, SA, Australia
| |
Collapse
|
21
|
Hill K, Sharp R, Childs J, Esterman A, Le Leu R, Juneja R, Jesudason S. Cannulation practices at haemodialysis initiation via an arteriovenous fistula or arteriovenous graft. J Vasc Access 2019. [PMID: 31423945 DOI: 10.1177/1129729819869093.] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
INTRODUCTION A functioning long-term vascular access is required for haemodialysis therapy; however, establishing this can be challenging in the setting of advanced age and vessels damaged by diabetes. Complications include the inability to insert two needles for the treatment resulting in miscannulation trauma and in some cases insertion of a temporary central venous access device. The broad objective of this review is to define the evidence base regarding cannulation practices in the initiation of haemodialysis via an arteriovenous fistula or an arteriovenous graft. METHODS This review uses the framework recommended by the Joanna Briggs Institute and the process by which papers were included or excluded followed the standard Preferred Reporting Items for Systematic Reviews and Meta-Analyses group approach. A total of 20 primary research studies met the inclusion criteria. RESULTS Cannulation in the 10- to 15-week period rather than delaying past this time frame is associated with the best outcomes. New vascular access given time to mature through single-needle haemodialysis treatments may improve long-term patency. Duplex ultrasound mapping prior to initiation of cannulation supports the clinical decision-making process on timing of and selection of cannulation sites. CONCLUSION Cannulation trauma at the initiation of haemodialysis could potentially be reduced with a strategy of incremental haemodialysis using single-needle treatment supported with duplex ultrasonography assessment to 'map' the vascular access as a guide for clinicians prior to cannulation initiation.
Collapse
Affiliation(s)
- Kathleen Hill
- University of South Australia, Adelaide, SA, Australia
| | - Rebecca Sharp
- University of South Australia, Adelaide, SA, Australia
| | - Jessie Childs
- University of South Australia, Adelaide, SA, Australia
| | | | - Richard Le Leu
- Central and Northern Adelaide Renal and Transplantation Service, Adelaide, SA, Australia
| | - Rajiv Juneja
- Southern Adelaide Local Health Network, Adelaide, SA, Australia
| | - Shilpa Jesudason
- Central and Northern Adelaide Renal and Transplantation Service, Adelaide, SA, Australia
| |
Collapse
|
22
|
Affiliation(s)
- Jovana Maric
- School of Health SciencesUniversity of South Australia Adelaide South Australia Australia
| | - Jessie Childs
- SANSOM Research InstituteUniversity of South Australia Adelaide South Australia Australia
| | - Adrian Esterman
- UniSA Cancer Research InstituteUniversity of South Australia Adelaide South Australia Australia
- Australian Institute of Tropical Health and MedicineJames Cook University Townsville Queensland Australia
| |
Collapse
|
23
|
Thoirs KA, Childs J. Are Ultrasound Measurements of Achilles Tendon Size Reliable? A Systematic Review of Rater Reliability. Ultrasound Med Biol 2018; 44:2476-2491. [PMID: 30154035 DOI: 10.1016/j.ultrasmedbio.2018.07.011] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/08/2018] [Revised: 07/04/2018] [Accepted: 07/13/2018] [Indexed: 06/08/2023]
Abstract
Ultrasound measurements of Achilles tendon size are used to assess the tendon's response to exercise, aging, rehabilitation, tendon loading and healing. It is important to understand and minimise the measurement error that occurs with these measurements. This review identified and synthesised studies reporting on intra- and inter-rater reliability of ultrasound measurements of Achilles tendon size. Analysis of 21 studies revealed that good to excellent intra- and inter-rater reliability can be achieved for ultrasound measurements of Achilles tendon size. Reliability can be optimised by using one experienced operator, standardising transducer pressure and orientation and averaging two or three measurements. There was a high risk of methodological bias across the included studies. Reporting of reliability studies needs to be improved by the use of existing reporting guidelines and expansion of these guidelines to include important elements of ultrasound imaging.
Collapse
Affiliation(s)
- Kerry A Thoirs
- International Centre of Allied Health Evidence, School of Health Sciences, University of South Australia, Adelaide, South Australia 5001, Australia.
| | - Jessie Childs
- School of Health Sciences, University of South Australia, Adelaide, South Australia 5001, Australia
| |
Collapse
|
24
|
Childs J, Lamb K. The inter-rater and intra-rater reliability of a recently developed equation to determine liver volume using three simple two-dimensional ultrasound measurements. Sonography 2018. [DOI: 10.1002/sono.12161] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
25
|
Moderiano M, McEvoy M, Childs J, Esterman A. Safety of Ultrasound Exposure: Knowledge, Attitudes, and Practices of Australasian Sonographers. Journal of Diagnostic Medical Sonography 2018. [DOI: 10.1177/8756479318791512] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Introduction: While perceived as safe, diagnostic ultrasound has the potential to cause biological effects on the body tissues. The aim of this study was to evaluate knowledge, attitudes, and practices of Australasian sonographers on bioeffects and safety of ultrasound scanning. Methods: Focus groups were used to develop a questionnaire to explore knowledge, attitudes, and practices of ultrasound safety, which was then distributed to Australasian sonographers. Thematic (focus groups) and descriptive (questionnaires) analyses were undertaken. Results: A 37-item questionnaire addressed knowledge, attitudes, and practices of ultrasound safety. In 47 collected responses, sonographers demonstrated good familiarity of thermal index (TI) (79%), mechanical index (MI) (68%), and “as low as reasonably achievable” (ALARA) principle (85%). However, most sonographers could not accurately define TI (13%) and had poor knowledge of safety guidelines relating to TI (19%) and MI (14%). Over 30% were uncertain about their attitudes to ultrasound safety issues. While 52% always and 30% most of the time adhere to ALARA, 37% of sonographers reported never monitoring TI and MI. Discussion: While familiar with safety terms, knowledge of safety guidelines was lacking. Many sonographers were uncertain about their attitudes to the safety of scans, and safety practices involving monitoring for bioeffects were not a high priority.
Collapse
Affiliation(s)
| | - Maureen McEvoy
- Sansom Institute of Health Research, University of South Australia, Australia
| | - Jessie Childs
- Sansom Institute of Health Research, University of South Australia, Australia
| | - Adrian Esterman
- Sansom Institute of Health Research, University of South Australia, Australia
| |
Collapse
|
26
|
Sharp R, Childs J, Bulmer AC, Esterman A. The effect of oral hydration and localised heat on peripheral vein diameter and depth: A randomised controlled trial. Appl Nurs Res 2018; 42:83-88. [DOI: 10.1016/j.apnr.2018.06.013] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2017] [Revised: 04/26/2018] [Accepted: 06/14/2018] [Indexed: 10/28/2022]
|
27
|
Moderiano M, McEvoy M, Childs J, Esterman A. Safety of ultrasound exposure: Knowledge, attitudes and practices of Australasian sonographers. Sonography 2017. [DOI: 10.1002/sono.12113] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | - Maureen McEvoy
- Sansom Institute of Health Research, University of South Australia; Australia
| | - Jessie Childs
- Sansom Institute of Health Research, University of South Australia; Australia
| | - Adrian Esterman
- Sansom Institute of Health Research, University of South Australia; Australia
| |
Collapse
|
28
|
Affiliation(s)
- Kerry Thoirs
- School of Health Sciences; University of South Australia; SA Australia
| | - Kathryn Deed
- School of Health Sciences; University of South Australia; SA Australia
| | - Jessie Childs
- School of Health Sciences; University of South Australia; SA Australia
| |
Collapse
|
29
|
Abstract
Magnetic stimulation was used to assess central motor conduction times in a patient with multiple sclerosis before and after physiotherapy. A significant change in central motor conduction corresponding to clinical improvement was noted after physiotherapy.
Collapse
Affiliation(s)
- RH Kandler
- Department of Clinical Neurophysiology, The Royal Hallamshire Hospital, Sheffield
| | - J. Childs
- Department of Physiotherapy, Retford Hospital, Bassetlaw Health Authority
| |
Collapse
|
30
|
Salazar LG, Higgins D, Childs J, Coveler AL, Liao J, Stanton S, Gooley T, Standish LJ, Sasagawa M, DISIS ML. Abstract P2-11-03: Phase I/II randomized study of combination immunotherapy with or without polysaccharide krestin (PSK) concurrently with a HER2 ICD peptide-based vaccine in patients with stage IV breast cancer receiving HER2-targeted monoclonal antibody therapy. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p2-11-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Natural killer (NK) cell defects, commonly seen in metastatic breast cancer (MBC) lead to decrease in dendritic cell (DC) maturation, proinflammatory cytokine production, and tumor infiltrating T-cells (TILs). This results in a protumorigenic Th2 immune microenvironment with low response rates to immunotherapy (i.e., immune checkpoint blockade) and standard chemotherapy. PSK, a potent TLR-2 agonist, activates NK cells to produce IFN-γ and IL-12 and promote DC maturation/differentiation toward a Th1 profile in the tumor microenvironment which results in antigen specific TIL that can eradicate tumor. The combination immunotherapy of PSK and HER2 directed therapy described here, aims at inducing Th1 immunity and tumor specific T-cells. This proposed regimen could eradicate microscopic residual disease and prevent recurrence in optimally treated HER2+ MBC patients. Moreover, the regimen could result in enhanced trafficking of TILs to the site of tumor and improve the efficacy of checkpoint inhibitors and other therapies. A phase I/II randomized 2 arm study of combination immunotherapy with oral PSK (or placebo) given with a HER2 peptide vaccine and HER2 mAb therapy (trastuzumab (TZ) +/- pertuzumab (PZ)) was initiated to assess the safety of the approach and evaluate the effect of PSK on NK cell activity, pro-inflammatory cytokine/chemokine profile; and HER2 vaccine-induced T cell immunity.
Methods: Up to 30 patients with HER2+ MBC who are without evidence of disease after definitive therapy and currently on maintenance TZ +/- PZ are enrolled and randomly assigned in equal numbers to 1 of 2 arms (15 patients/arm): Arm 1: HER2 ICD vaccine + placebo or Arm 2: HER2 ICD vaccine + PSK. All patients receive concomitant treatment with 4 months of daily oral PSK or placebo, 3 monthly intradermal HER2 ICD vaccinations and continued TZ +/- PZ. Toxicity is evaluated per CTEP CTCAE 4.0, during and post vaccination. Serial blood draws for immunologic evaluation of NK cell activity and antigen-specific T cell immunity via flow cytometry and IFN-γ ELISPOT, respectively; and pro-inflammatory cytokines/chemokines.
Results: 24 subjects have been enrolled and 60 vaccines have been given. 16 subjects have completed all 3 vaccines and PSK/placebo; and 6 subjects are currently in progress. 2 subjects received < 3 vaccines and were taken off study. Of 144 reported adverse events (AEs), 97% were Grade 1-2; 66 (46%) were possibly, probably, or definitely related to study treatment. Most common AEs are injection site reaction and flu-like symptoms. There have been a total of four Grade 3 AEs, 1 episode of self-limited nausea/vomiting attributed to study treatment; and cognitive disturbance, fatigue, and lymphopenia all in 1 subject and attributed to disease progression. There have been no Grade 4 AEs. Immunologic analyses are ongoing and will be presented along with completed clinical data on all patients.
Conclusion: Combination immunotherapy with PSK/placebo and concurrent HER2 directed therapy is safe and well-tolerated. Further ongoing immunologic studies will help define the immunogenicity of the approach.
Citation Format: Salazar LG, Higgins D, Childs J, Coveler AL, Liao J, Stanton S, Gooley T, Standish LJ, Sasagawa M, DISIS ML. Phase I/II randomized study of combination immunotherapy with or without polysaccharide krestin (PSK) concurrently with a HER2 ICD peptide-based vaccine in patients with stage IV breast cancer receiving HER2-targeted monoclonal antibody therapy. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-11-03.
Collapse
Affiliation(s)
- LG Salazar
- University of Washington, Seattle, WA; Bastyr University, Kenmore, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - D Higgins
- University of Washington, Seattle, WA; Bastyr University, Kenmore, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - J Childs
- University of Washington, Seattle, WA; Bastyr University, Kenmore, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - AL Coveler
- University of Washington, Seattle, WA; Bastyr University, Kenmore, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - J Liao
- University of Washington, Seattle, WA; Bastyr University, Kenmore, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - S Stanton
- University of Washington, Seattle, WA; Bastyr University, Kenmore, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - T Gooley
- University of Washington, Seattle, WA; Bastyr University, Kenmore, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - LJ Standish
- University of Washington, Seattle, WA; Bastyr University, Kenmore, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - M Sasagawa
- University of Washington, Seattle, WA; Bastyr University, Kenmore, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - ML DISIS
- University of Washington, Seattle, WA; Bastyr University, Kenmore, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| |
Collapse
|
31
|
Rengan R, Baker K, Salazar L, Childs J, Higgins D, Redman M, Reichow J, Disis ML. Abstract P2-11-05: Overall survival in inflammatory breast cancer patients receiving Her-2 Neu directed tumor vaccine therapy: Matched comparison with SEER registry patients. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p2-11-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Patients with inflammatory breast cancer (IBC) have a poor prognosis, primarily due to distant dissemination. Additionally, IBC patients have an increased rate of HER2 overexpression when compared to patients with non-inflammatory breast cancer. The forms the rationale for HER2 directed tumor vaccine therapy in these patients. The purpose of this study was to examine overall survival in IBC patients receiving HER2 directed tumor vaccine therapy when compared with matched control patients from the SEER Registry.
Methods
Patients with diagnosis of Stage III or IV HER2 positive IBC having completed standard initial therapy and without evidence of disease received HER2 vaccinations after being enrolled on 5 prospective clinical trials. Overall survival data were pooled and analyzed. A control group of matched IBC patients were identified by querying the SEER database from 1997-2011. The control group was identified as any individual in the database with a code for IBC. A secondary analysis comparing survival in HER2 positive IBC vs HER2 negative IBC patients was performed by querying the SEER database from 2010 onwards, the time point when the HER2 status was coded in the database. Propensity score adjustment were made to the control group to account for any imbalances between groups in measured covariates such as stage, race, age, sex, and era of enrollment and the time interval from diagnosis to enrollment on vaccine trial (median ∼2 years).
Results
A total of 37 IBC patients received HER2 directed vaccine therapy and 676 patients were identified for the SEER control group; Stage at enrollment: stage IIIB: 30 patients in the vaccine group and 639 patients in the control group; stage IIIC: 1 patient in the vaccine group and 15 patients in the control group; stage IV 6 patients in the vaccine group and 22 in the control group. The median survival of the overall population was 112 months for the vaccine group and 47 months for the control group (p=0.04). After using propensity scores to adjust the control for imbalances in measured covariates, the median survival for the overall population was 112 months for the vaccine group and 37 months for the control group (p=0.03). There was no difference in survival between HER2 positive and HER2 negative IBC patients in the control group (p=0.6).
Conclusion
These results demonstrate promising overall survival in HER2 positive IBC patients receiving HER2 directed vaccine therapy after initial therapy. Propensity matching was performed to adjust for imbalances in measured covariates and resulted in a modest decrease in survival of the control group after adjustment, suggesting that the vaccine trial group had relatively unfavorable pre-treatment characteristics. Despite these unfavorable characteristics, patients receiving vaccine had a median survival of 112 months. These results must be further confirmed in a prospective randomized trial.
Citation Format: Rengan R, Baker K, Salazar L, Childs J, Higgins D, Redman M, Reichow J, Disis ML. Overall survival in inflammatory breast cancer patients receiving Her-2 Neu directed tumor vaccine therapy: Matched comparison with SEER registry patients. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-11-05.
Collapse
Affiliation(s)
- R Rengan
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - K Baker
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - L Salazar
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - J Childs
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - D Higgins
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - M Redman
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - J Reichow
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - ML Disis
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| |
Collapse
|
32
|
Marquez-Manriquez J, Ramos E, Durazo-Bustamante F, Rastetter L, Koehnlein M, Brooussard E, Coveler A, Kim R, Childs J, Gad E, Disis M. 2011 Multi-antigen vaccination for colon cancer treatment and prevention. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(15)30041-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
33
|
Peck CN, Childs J, McLauchlan GJ. Inferior outcomes of total knee replacement in early radiological stages of osteoarthritis. Knee 2014; 21:1229-32. [PMID: 25205527 DOI: 10.1016/j.knee.2014.08.018] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/29/2013] [Revised: 08/17/2014] [Accepted: 08/19/2014] [Indexed: 02/02/2023]
Abstract
BACKGROUND Total knee replacement (TKR) for osteoarthritis (OA) is a common and successful operation; the severity of radiographic changes plays a key role as to when it should be performed. This study investigates whether an early radiological grade of OA has an adverse effect on the outcome of TKR in patients with arthroscopically confirmed OA. METHODS Between January 2006 and January 2011 data was collected prospectively on all patients undergoing a primary TKR for OA. We included all patients with a Kellgren-Lawrence score of two or less on their pre-operative radiograph who had had an arthroscopy to confirm significant OA. Our primary outcomes were the Oxford Knee Score (OKS) and a satisfaction rating. RESULTS Over the study period 1708 primary TKRs were performed in 1381 patients. We identified 44 TKRs in 43 patients with a Kellgren-Lawrence score of two or less on their pre-operative radiograph. In this group the mean age was 63 years, 66% were female and the mean BMI was 31.7 kg/m(2). At a mean follow-up of 37 months the mean OKS was only 30 points compared to 36 in all TKRs performed over the same period (p=0.0004). Only 68% were either satisfied or very satisfied. Eight knees (18%) underwent further surgery, three (6.8%) of which were revision procedures, compared to a revision rate of 1.6% in all patients. CONCLUSION The outcomes of TKR in patients with early radiological changes of OA are inferior to those with significant radiological changes and should be performed with caution. LEVEL OF EVIDENCE Level IV case-series.
Collapse
Affiliation(s)
- C N Peck
- Department of Orthopaedic Surgery, Chorley District Hospital, Lancashire Teaching Hospitals NHS Trust, Preston, United Kingdom.
| | - J Childs
- Department of Orthopaedic Surgery, Chorley District Hospital, Lancashire Teaching Hospitals NHS Trust, Preston, United Kingdom
| | - G J McLauchlan
- Department of Orthopaedic Surgery, Chorley District Hospital, Lancashire Teaching Hospitals NHS Trust, Preston, United Kingdom
| |
Collapse
|
34
|
Affiliation(s)
- Kathryn Deed
- School of Health Sciences; University of South Australia; Adelaide South Australia Australia
| | - Jessie Childs
- School of Health Sciences; University of South Australia; Adelaide South Australia Australia
| | - Kerry Thoirs
- School of Health Sciences; University of South Australia; Adelaide South Australia Australia
| |
Collapse
|
35
|
Liao J, Cecil D, Reichow J, Parker S, Higgins D, Childs J, Broussard E, Coveler A, Salazar L, Disis M. A phase I trial of a DNA plasmid-based vaccine targeting insulin-like growth factor binding protein-2 (IGFBP-2) in patients with advanced ovarian cancer: Preliminary safety and immunogenicity. Gynecol Oncol 2014. [DOI: 10.1016/j.ygyno.2014.03.094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
36
|
Reichow J, Higgins D, Parker S, Childs J, Disis ML, Salazar LG. Abstract P2-15-02: The efficacy of recruitment and retention strategies for research subjects in an early phase investigator-initiated breast cancer trial. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p2-15-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: One of the biggest challenges faced by investigators is the implementation of effective strategies to improve the recruitment and retention of research participants. This is especially true for investigator-initiated, federally funded (e.g. NIH and DOD), early phase clinical trials that involve the treatment of serious diseases such as metastatic breast cancer (MBC). These studies may face additional barriers to participation since patients have often already undergone maximal treatment and are usually not in a financial position that for allows the travel and lodging necessary to receive further investigative treatment. Moreover, efficacy and toxicology in early phase clinical trials are unknown. Thus, when study budget constraints do not allow monetary incentives to participation, it is difficult to provide motivation for patients to enroll and remain adherent to the protocol requirements. However, many MBC patients are motivated to join clinical trials for altruistic purposes alone, and evidence supports that the researcher-patient relationship may be the most important factor in clinical trial participation. Recognizing that many patients are willing to participate if provided the appropriate resources despite limited monetary incentives, we developed a system to improve patient recruitment and retention to our studies, which are primarily federally funded. We report here on the strategies developed and used by our group to recruit and retain patients in a federally-funded investigator-initiated phase I/II vaccine study in MBC patients.
Methods: This study was funded by the NIH/NCI and involved infusion of HER2 specific T cells in HER2+ MBC patients after completing in vivo priming with a HER2 vaccine. It required 11 visits to Seattle, Washington. Working with agencies that offer free services to patients enrolled in clinical trials, a list of available resources was compiled and a visit flowchart with specific information on travel and lodging resources (e.g. Angel Flights and ACS sponsorship), local transportation and entertainment was developed. During screening, patients were given the list of resources and trial information. An email system was used to quickly communicate and follow-up with patients. Eligible patients were given the visit flowchart to help with their planning of study visits. An enrollment packet was provided at the first visit with a calendar to keep track of the visit schedule. Coordination of care between the patient's primary oncologist and the research staff was maintained throughout the study.
Results: 17 of 19 patients enrolled were not from Washington State. Two out-of-state patients withdrew early from the trial for reasons unrelated to disease progression or toxicity; one subject completed 8 visits and enrolled in another study and the other completed 2 visits and discontinued the trial to resume chemotherapy.
Conclusion: We have developed a successful system to enroll and retain patients in a trial requiring multiple study visits. Development and implementation of site-specific standard procedures are critical to improve study participation and retention, especially when patients receive no financial benefit.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P2-15-02.
Collapse
Affiliation(s)
- J Reichow
- University of Washington, Seattle, WA
| | - D Higgins
- University of Washington, Seattle, WA
| | - S Parker
- University of Washington, Seattle, WA
| | - J Childs
- University of Washington, Seattle, WA
| | - ML Disis
- University of Washington, Seattle, WA
| | | |
Collapse
|
37
|
Salazar LG, Slota M, Higgens D, Coveler A, Dang Y, Childs J, Bates N, Guthrie K, Waisman J, Disis ML. Abstract P5-16-04: A phase I study of a DNA plasmid based vaccine encoding the HER-2/neu intracellular domain in subjects with HER2+ breast cancer. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p5-16-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
HER2+ breast cancer (BC) is associated with early disease relapse, usually to distant sites. This would suggest relapse is due to residual microscopic disease. Generation of vaccine-induced HER2-specific CD4+ T helper immunity (Th1) may result in immunologic eradication of residual HER2+ tumor cells and subsequent development of immunologic memory and epitope spreading (ES), which has been associated with a survival benefit in vaccinated BC patients. We have shown HER2 peptide-based vaccines can generate immunity in BC however, more recently we developed a plasmid DNA based vaccine (pNGVL3-hICD) which may have additional advantages over synthetic peptides. DNA vaccines offer a strategy to immunize against multiple tumor antigens and are able to elicit both CTL and Th1 immunity. Plasmid DNA can also remain at the vaccine site, providing a constant source of antigen. Intradermal (i.d.) delivery of DNA vaccines with GM-CSF as adjuvant may enhance immunogenicity due to local influx of dermal Langerhans cells. We have recently completed a phase I trial utilizing pNGVL3-hICD in optimally treated stage III and IV HER2+ BC patients and have defined vaccine safety profile, optimal dose and schedule; and demonstrated vaccine biologic activity.
Methods: A total of 66 subjects with stage III and IV HER2+ BC in complete remission were enrolled sequentially into 1 of 3 pNGVL3-hICD dose arms (22 subjects/arm): Arm 1=10µg, Arm 2=100 µg, and Arm 3 = 500µg. All vaccines were admixed with 100µg GM-CSF and given i.d. monthly for a total of 3 vaccines. Toxicity was assessed at baseline, during vaccination and at follow-up. Immune responses to HER ICD and ECD were assessed with IFN-γ ELISPOT at baseline and serially through week 60 post-vaccination. Linear regression analysis was used to compare differences in immune responses from baseline over the whole study period between dose arms. Vaccine site skin biopsies and peripheral lymphocytes were serially analyzed for plasmid persistence via RT-PCR.
Results: 64 subjects (20 in Arm 1; 22 in Arm 2; 22 in Arm 3) completed 3 vaccines. Age, stage/status, number of previous chemotherapy regimens, and use of bisphosphonate and trastuzumab therapies was similar across dose arms. Vaccine-related toxicity was primarily Grade 1/2 injection site reactions, myalgias, arthralgias and not significantly different between arms; no cardiac or grade IV toxicity was observed. Immune responses to HER2 ICD were significantly better in Arms 2 and 3 vs Arm 1 (p = 0.001 and 0.002, respectively) but not statistically different between Arms 2 and 3. 38 patients had DNA plasmid persistence at the vaccination site with no difference between arms. There has been no detection of DNA plasmid in lymphocytes from patients in all arms. Analyses of survival and ES (HER ECD immune responses) are on-going and will be presented.
Conclusions: pNGVL3-hICD was safe and effectively induced persistent HER2 ICD specific Th1 immunity without increased cardiac toxicity. Moreover, immunity was present more than 1 year after end of vaccination, indicative of vaccine-induced immunologic memory.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P5-16-04.
Collapse
Affiliation(s)
- LG Salazar
- University of Washington, Seattle, WA; BREASTLINK, Hawthorne, CA
| | - M Slota
- University of Washington, Seattle, WA; BREASTLINK, Hawthorne, CA
| | - D Higgens
- University of Washington, Seattle, WA; BREASTLINK, Hawthorne, CA
| | - A Coveler
- University of Washington, Seattle, WA; BREASTLINK, Hawthorne, CA
| | - Y Dang
- University of Washington, Seattle, WA; BREASTLINK, Hawthorne, CA
| | - J Childs
- University of Washington, Seattle, WA; BREASTLINK, Hawthorne, CA
| | - N Bates
- University of Washington, Seattle, WA; BREASTLINK, Hawthorne, CA
| | - K Guthrie
- University of Washington, Seattle, WA; BREASTLINK, Hawthorne, CA
| | - J Waisman
- University of Washington, Seattle, WA; BREASTLINK, Hawthorne, CA
| | - ML Disis
- University of Washington, Seattle, WA; BREASTLINK, Hawthorne, CA
| |
Collapse
|
38
|
Warren JM, Iversen CM, Garten CT, Norby RJ, Childs J, Brice D, Evans RM, Gu L, Thornton P, Weston DJ. Timing and magnitude of C partitioning through a young loblolly pine (Pinus taeda L.) stand using 13C labeling and shade treatments. Tree Physiol 2012; 32:799-813. [PMID: 22210530 DOI: 10.1093/treephys/tpr129] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
The dynamics of rapid changes in carbon (C) partitioning within forest ecosystems are not well understood, which limits improvement of mechanistic models of C cycling. Our objective was to inform model processes by describing relationships between C partitioning and accessible environmental or physiological measurements, with a special emphasis on short-term C flux through a forest ecosystem. We exposed eight 7-year-old loblolly pine (Pinus taeda L.) trees to air enriched with (13)CO(2) and then implemented adjacent light shade (LS) and heavy shade (HS) treatments in order to manipulate C uptake and flux. The impacts of shading on photosynthesis, plant water potential, sap flow, basal area growth, root growth and soil CO(2) efflux rate (CER) were assessed for each tree over a 3-week period. The progression of the (13)C label was concurrently tracked from the atmosphere through foliage, phloem, roots and surface soil CO(2) efflux. The HS treatment significantly reduced C uptake, sap flow, stem growth and fine root standing crop, and resulted in greater residual soil water content to 1 m depth. Soil CER was strongly correlated with sap flow on the previous day, but not the current day, with no apparent treatment effect on the relationship. Although there were apparent reductions in new C flux belowground, the HS treatment did not noticeably reduce the magnitude of belowground autotrophic and heterotrophic respiration based on surface soil CER, which was overwhelmingly driven by soil temperature and moisture. The (13)C label was immediately detected in foliage on label day (half-life = 0.5 day), progressed through phloem by Day 2 (half-life = 4.7 days), roots by Days 2-4, and subsequently was evident as respiratory release from soil which peaked between Days 3 and 6. The δ(13)C of soil CO(2) efflux was strongly correlated with phloem δ(13)C on the previous day, or 2 days earlier. While the (13)C label was readily tracked through the ecosystem, the fate of root C through respiratory, mycorrhizal or exudative release pathways was not assessed. These data detail the timing and relative magnitude of C flux through various components of a young pine stand in relation to environmental conditions.
Collapse
Affiliation(s)
- J M Warren
- Environmental Sciences Division, Oak Ridge National Laboratory, Oak Ridge, TN, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Salazar LG, Lu H, Gray H, Higgins D, Childs J, Yushe D, Slota M, Parker S, Disis ML. P1-13-04: Phase II Study of Topical Imiquimod and Abraxane for Treatment of Breast Cancer Cutaneous Metastases. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p1-13-04] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Breast cancer (BC) cutaneous lesions can present as local chest wall recurrence or isolated sites of metastatic disease. Current treatments with full thickness chest wall resection, radiation therapy and chemotherapy are not curative; and have significant morbidity and poor overall response rates. Combining local immunomodulation and systemic chemotherapy may be more effective in treating cutaneous disease. Topical imiquimod (IMQ), a TLR-7 agonist, has shown clinical activity against cutaneous metastasis. Pre-clinical studies have shown IMQ to stimulate Th1 cytokine secretion and up-regulate immune co-stimulatory molecules at the tumor site; resulting in augmented tumor specific T cell immunity and tumor growth inhibition. Use of paclitaxel in BC, has demonstrated immunostimulatory effects of increased serum IFN-γ and enhanced NK/LAK cell activity. Abraxane (albumin-bound paclitaxel) may be used in conjunction with IMQ as steroid pre-treatment is not required. We hypothesize the immune effects of Abraxane may synergize and augment the IMQ anti-tumor effects, resulting in greater clinical response. A phase II single-arm study of chemoimmunotherapy with topical IMQ and Abraxane was initiated to determine its safety and therapeutic efficacy; and examine its effect on augmenting endogenous tumor specific immunity and inducing tumor molecular alterations associated with inhibition of tumor growth and/or common pathways of BC immune escape.
Materials and Methods: Up to 15 BC patients with cutaneous lesions no longer amenable to standard therapy are enrolled and receive 3 treatment cycles. A treatment cycle consist of topical 5% IMQ to target lesions 4 days/week (wk.) and Abraxane 100 mg/m2 on Days 1, 8, 15 every 28 Days. Toxicity is evaluated per CTCAE v3.0 on Days 1, 8, 15 of each cycle and wks. 13, 16, 20, 24. Target lesion antitumor activity is assessed per modified WHO criteria (Complete response (CR); Partial response (PR); Stable disease (SD); Progressive disease (PD)) at baseline, wks. 4, 8, 12, 16, 20, 24. 2-mm target lesion skin biopsies are obtained pre-and post-treatment for histologic analysis and RT-PCR analysis of a 7 IFN-related gene signature associated with tumor inhibition. Immunity to HER2, IGFBP-2, TOPO-IIα, p53 and serum TGF-β levels are evaluated at baseline and wks. 12, 24 with IFN-γ ELISPOT and ELISA, respectively.
Results: 10 patients have been enrolled. Median (range) values include: age, 54 years (48-92), time from metastatic diagnosis, 134 months (58-728), prior chemotherapy regimens, 5 (2-10). 5/10 patients had received prior local therapy, e.g., radiation. 5/10, 4/10, and 2/10 patients had triple negative, HER2+ and ER+/PR+ tumors, respectively. In 5 patients completing 3 treatment cycles, overall response rate (ORR) = 100% (3 CR, 2 PR). In the 5 patients who completed 1–2 treatment cycles, ORR = 80% (2 PR, 2 SD, 1 PD). Treatment related toxicity is primarily grade I/II neutropenia, anemia; grade I skin toxicity. Immunologic analyses are ongoing and will be presented with completed clinical data on all patients.
Conclusions: Chemoimmunotherapy with topical IMQ and Abraxane is well-tolerated and shows excellent clinical efficacy in treating metastatic cutaneous lesions in heavily pretreated BC patients.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P1-13-04.
Collapse
Affiliation(s)
| | - H Lu
- 1University of Washington, Seattle, WA
| | - H Gray
- 1University of Washington, Seattle, WA
| | - D Higgins
- 1University of Washington, Seattle, WA
| | - J Childs
- 1University of Washington, Seattle, WA
| | - D Yushe
- 1University of Washington, Seattle, WA
| | - M Slota
- 1University of Washington, Seattle, WA
| | - S Parker
- 1University of Washington, Seattle, WA
| | - ML Disis
- 1University of Washington, Seattle, WA
| |
Collapse
|
40
|
Higgins DM, Childs J, Parker S, Disis ML, Salazar LG. OT3-01-19: Phase II Study of Topical Imiquimod and Weekly Abraxane for the Treatment of Breast Cancer Cutaneous Metastases. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-ot3-01-19] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Breast cancer (BC) cutaneous lesions present as local chest wall recurrence or as isolated sites of metastatic disease. The treatment of cutaneous lesions is challenging and includes chest wall resection, local radiation therapy, and/or salvage chemotherapy which is not curative, associated with significant morbidity, and results in overall response rates of 20–30%. Thus, investigation of novel treatment strategies is warranted. This study incorporates multimodality treatment with topical imiquimod, a TLR-7agonist which generates an immune signal similar to that of pathogenic bacteria and Abraxane, a conventional systemic chemotherapy with potential immunostimulatory effects. Combined, these two agents provide local and systemic strategies which are potentially synergistic; and more effective than as single-agents in treating and controlling cutaneous disease.
Trial design: A Phase II single arm, non-randomized study. Patients will be sequentially enrolled and receive a maximum of 3 treatment cycles. A treatment cycle consists of topical imiquimod daily to target lesions for 4 days/week for 4 weeks in addition to Abraxane on Days 1, 8, and 15 every 28 days. Toxicity will be evaluated weekly during treatment then monthly for four months. Defined lesions are assessed at baseline and monthly. Skin biopsies are obtained pre and post treatment for histologic analysis and RT-PCR analysis of a 7 IFN-related gene signature previously associated with tumor inhibition. Immunity to BC antigens and serum TGF-β levels are also evaluated.
Aims: To evaluate the safety and anti-tumor effects of chemoimmunotherapy with topical imiquimod and Abraxane.
Eligibility criteria: Patients with progressive or relapsed BC after standard therapy who 1) have measurable cutaneous metastatic lesions, 2) are at least 7 days from last chemotherapy, 30 days from local radiotherapy and/or systemic steroids, 3) have adequate blood counts and 4) no history of active autoimmune disease. Bisphosphonates, trastuzumab, and/or hormonal therapy is allowed.
Statistical methods: Antitumor activity of target lesions will be assessed per modified WHO criteria. Complete response (CR)-complete clearance of lesions; Partial response (PR) ≥ 50% decrease in lesion size; Stable disease (SD) < 50% decrease in lesion size; Progressive disease (PD) increase in ≥ 25% lesion size). Historical overall response rates (ORR) with second and third line salvage chemotherapy range from 20–30%, with CR rates less than 2%. Based on these numbers, an ORR of 50% or a CR rate of 10% will be used as benchmarks for success (i.e., ≥8 responses or ≥2 CRs among 15 patients (observed ORR of ≥ 53% or observed CR rate of ≥ 13%) to consider the treatment worthy of further study. As a measure of the precision of the estimate of ORR achievable with 15 patients, if the response rate is 60%, we will be 80% confident that the observed RR is within 0.16 of the true RR with 15 patients treated. Toxicity will be evaluated by CTCAE v. 3.0 and descriptive statistics will be used to summarize changes from baseline and for reporting of immunological parameters.
Accrual: 10 patients received treatment with a target accrual of 15.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr OT3-01-19.
Collapse
Affiliation(s)
| | - J Childs
- 1University of Washington, Seattle, WA
| | - S Parker
- 1University of Washington, Seattle, WA
| | - ML Disis
- 1University of Washington, Seattle, WA
| | | |
Collapse
|
41
|
Higgins DM, Childs J, Parker S, Guthrie KA, Disis ML, Salazar LG. OT1-02-10: Phase I-II Study of HER2 Vaccination with Poly(I) • Poly(C12U) (Ampligen®) as an Adjuvant in Optimally Treated Breast Cancer Patients. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-ot1-02-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Despite improved response rates and overall survival, many HER2+ breast cancer (BC) patients have disease relapse suggesting residual microscopic disease. HER2 vaccines given with adjuvants that can enhance, sustain, and skew antigen immunogenicity toward a Th1 phenotype could induce robust tumor-specific Th1 immunity resulting in immunologic eradication of residual tumor cells and potentially prevent relapse. One such adjuvant is Ampligen which is highly selective as a TLR-3 agonist. Our pre-clinical studies show a dose effect in the tumor prevention efficacy of Ampligen when given as an adjuvant with vaccines. We hypothesize HER2 peptide vaccination given with standard adjuvant 100mcg GMCSF and Ampligen can induce a higher incidence and magnitude of protective HER2−specific Th1 immunity than with GMCSF alone.
Trial design: Phase I-II randomized 2-stage HER2 vaccine study. Stage I will enroll 40 patients (10/arm) into one of 4 Ampligen dose arms (4, 20, 79, or 495 mcg + HER2 vaccine). The Ampligen “maximum biologic dose” (MBD), the dose with the highest incidence/magnitude of immune response and lowest incidence of toxicity will be defined. Stage II will enroll 48 patients (24/arm) receiving Ampligen MBD + HER2 vaccine + GMCSF or HER2 vaccine + GMCSF to evaluate if Ampligen MBD increases the incidence and magnitude of immunity vs HER2 vaccine + GMCSF alone. Patients will be enrolled sequentially and randomized equally into all arms via a permuted block design. Patients will receive 3 monthly vaccines. Toxicity and immune response will be assessed.
Aims: 1) To evaluate toxicity and define the MBD of Ampligen as an adjuvant with HER2 vaccination 2) determine if Ampligen MBD when combined with GMCSF as adjuvant and HER2 vaccination increases incidence/magnitude of HER2 Th1 immunity compared to standard GMCSF alone.
Eligibility criteria: Stage II–IV HER2+ BC patients who: 1) have completed definitive standard treatment, and in clinical remission 2) 14 days post chemotherapy and steroids 3) have adequate blood counts 4) are off trastuzumab 5) have no active autoimmune disease.
Statistical methods: In aim 1, we expect mild toxicity between the 4 dose arms, thus lack of efficacy based on incidence of immune response will be evaluated. Six responses must be observed within a dose arm to move forward based on historical 60% response rate (RR) with standard GMCSF (probability of continuing if true RR is 40% and 70% is 0.17, 0.85, respectively). In aim 2, 24 patients/arm provides 80% power to detect 40% difference in incidence of immune response between the 2 groups (Pearson chi-square test, two-sided alpha of 0.05) and 82% power to assess a 0.85 SD unit difference in change between control and MBD, based on a 2-sample t-test (p=0.05) and effect size defined as the difference in the means divided by the common SD. Incidences of HER2 Th1 immunity will be compared across treatment arms via Pearson chi-square test; magnitude of immune response will be compared across groups via linear regression model.
Study Accrual: Target accrual is 88 patients: Stage 1 (n=40) and Stage II (n=48). There has been no accrual at this time.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr OT1-02-10.
Collapse
Affiliation(s)
- DM Higgins
- 1University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - J Childs
- 1University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - S Parker
- 1University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - KA Guthrie
- 1University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - ML Disis
- 1University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - LG Salazar
- 1University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| |
Collapse
|
42
|
Affiliation(s)
- S Bleibleh
- Department of Trauma and Orthopaedics, Scarborough General Hospital, Scarborough
| | - J Childs
- Orthopaedic Department, Royal Preston Hospital, Preston, Lancashire PR2 9HT
| | - M Baqai
- Department of Orthopaedics, Furness General Hospital, Barrow-in-Furness, Cumbria
| |
Collapse
|
43
|
Swensen RE, Childs J, Higgins D, Gooley T, Goff BA, Fintak PA, Buening B, Disis ML. A phase II trial of weekly nab-paclitaxel with GM-CSF as chemoimmunotherapy for platinum-resistant epithelial ovarian cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.5020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
44
|
Najim H, Childs J. A comparison of mental health assessment of mentally ill offenders by mental health professionals. Eur Psychiatry 2011. [DOI: 10.1016/s0924-9338(11)72495-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
BackgroundCriminal justice mental health teams were established in The United kingdom in the late nineties of the last century following the publication of the Reed Report 1991.Two teams were established in South Essex following the geographical locality of each team. Basildon and Thurrock and Southend.MethodsAn evaluation form was devised to record all essential areas of assessment.Twenty five assessment of each team were picked and evaluated randomly over a period of a three months. A comparison was done between the assessment of the two teams.ResultsReferring agency one from the west didn’t mention itThree of the west didn’t have the index offence;One of the east and two of the west didn’t have past forensic history.Three of the west and one of the east didn’t have risk assessment.One of the west didn’t have summary of concernsThree of both didn’t mention whether other professionals involved or not.DiscussionComparison between different teams is important to make sure that there is a standard format for assessment and whether it is used in all assessments.It has been shown that assessments are very good in general in both teams. There are some areas which need to be addressed and managed.12% of patients on the west didn’t have risk assessment which is very risky.ConclusionThis comparison has highlighted areas we need to take care off especially risk assessment and liaising with other agencies in managing theses very special group of patients.
Collapse
|
45
|
Salazar L, Higgins D, Childs J, Bates N, Dang Y, Slota M, Coveler A, Waisman J, Disis M. Phase I-II Study of Denileukin Diftitox (ONTAK®) in Patients with Advanced Refractory Breast Cancer. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-4130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: CD4+CD25+Foxp3+ regulatory T cells (Tregs) are potent suppressors of CD4+ and CD8+ T cells, produce the immunosuppressive cytokine TGF-β; and as such, may down-regulate immune responses to tumor antigens. Additionally, Tregs are increased in the peripheral blood (PB) and tumors of breast cancer patients; and are associated with poor prognosis. Depletion of PB and tumor-associated Tregs may induce anti-tumor immunity by augmenting anti-tumor effector T cells and enhancing endogenous tumor specific immunity. ONTAK®, a diphtheria/IL-2R fusion protein depletes PB Tregs when given intravenously (IV) and selectively targets tumor cells that overexpress IL-2R. Breast tumors have been shown to overexpress IL-2R which is associated with their malignant potential. We hypothesized that ONTAK® could (1) have direct anti-tumor activity in breast cancers that overexpress IL-2R, and (2) deplete Tregs resulting in generation of functional immune effector cells and enhanced anti-tumor immunity. A phase I-II study was conducted to evaluate the safety of IV ONTAK® and assess its effect on Tregs and endogenous immunity in patients with advanced refractory breast cancer.Materials and Methods: 15 patients with progressive stage IV breast cancer following standard therapy were sequentially enrolled and received IV ONTAK® 18 mcg/kg/day on Days1-5 every 21 days for a total of 6 cycles and/or maximal tumor response. Toxicity was evaluated on Days 1 8, and 14 of each cycle per CTEP CTCAE v3.0. Tumor response was evaluated per RECIST at baseline, and after cycles 3 and 6. PB was collected at baseline and after cycles 2, 4, and 6 for evaluation of Tregs, sIL-2R, and endogenous tumor-antigen specific T cell immunity to HER-2/neu (HER2), CEA, and MAGE-3 via RT-PCR, LUMINEX and IFN-γ ELISPOT assay, respectively. Expression of IL-2R in patient paraffin embedded tumor samples was analyzed by IHC analysis.Results: 15 subjects have been enrolled and 14/15 have completed treatment; median age is 58 years (range, 32-69) and median salvage regimens is 3 (range, 2-8). 7/14 subjects had triple negative tumors. 7 subjects completed 1-2 and 7 completed 3-6 ONTAK® cycles, respectively. 4 subjects who completed 6 cycles of ONTAK® had SD or PR per RECIST. ONTAK®-related toxicities have been primarily grade I and II fatigue, nausea, and headache; and transient grade 3 hypoalbuminemia and lymphopenia. Preliminary data in 2 subjects shows enhanced tumor-antigen specific T cell immunity defined as mean tumor antigen-specific T cell precursors:PBMC to CEA (pre- ONTAK® 1:250,000; post- ONTAK® 1:15,000) and HER2 (pre- ONTAK® 1:63,000; post- ONTAK® 1:6,312). Immunologic analyses are ongoing and will be presented along with clinical data on all patients.Conclusions: ONTAK® is well-tolerated when used as a salvage regimen in heavily pretreated breast cancer patients. Additionally, ONTAK® treatment can enhance endogenous immunity to known breast cancer antigens and potentially lead to more effective eradication of tumor.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 4130.
Collapse
Affiliation(s)
| | | | | | | | - Y. Dang
- 1University of Washington, WA,
| | | | | | | | | |
Collapse
|
46
|
Disis M, Dang Y, Bates N, Higgins D, Childs J, Slota M, Coveler A, Jackson E, Waisman J, Salazar L. Phase II Study of a HER-2/Neu (HER2) Intracellular Domain (ICD) Vaccine Given Concurrently with Trastuzumab in Patients with Newly Diagnosed Advanced Stage Breast Cancer. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-5102] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
HER2 is a tumor antigen in breast cancer and several trials have demonstrated that breast cancer patients can be immunized against this protein. We have developed HER2 peptide based vaccines that are aimed at eliciting CD4+ Th1 tumor antigen specific T cell responses. Th1 effectors provide immunologic memory, enhance cross priming which will allow the elaboration of tumor specific CD8+ T cells, and stimulate epitope spreading which we have shown to be a potential biomarker of clinical response. 52 patients will be enrolled with the primary objective to determine relapse free survival after active immunization. Eligible patients are newly diagnosed with Stage III (B or C) or Stage IV breast cancer and begin vaccination within 6 months of starting maintenance trastuzumab. This interim report will present data on the first 25 patients enrolled; 21 stage IV and 4 locally advanced patients. The vaccine is well tolerated with all adverse events (AE) being Grade I or 2. The most common AE is injection site reaction. Moreover, the combination of HER2 vaccination with trastuzumab did not result in additive cardiac toxicity in these patients. Immune responses were evaluated by IFN-gamma ELISPOT. To date, 88% of patients immunized developed significant immunity to the components of the ICD vaccine. The majority, 75%, developed robust immunity to the HER2 protein. Our group has recently demonstrated that a broadening of immunity throughout the HER2 protein, to components of the protein that weren't in the vaccine, i.e. epitope spreading, may be associated with improved survival in vaccinated patients. 63% of immunized patients demonstrated evidence of intramolecular epitope spreading. We questioned whether such high frequencies of homing Type 1 T cells might modulate the immunosuppressive tumor microenvironment, so we evaluated whether circulating serum immunosuppressive cytokines were impacted by immunization. TGF-beta is an immunosuppressive cytokine secreted by tumor stroma and regulatory T cells. We found that the levels of serum TGF-beta decreased significantly in the majority of patients after vaccination. We further analyzed the correlation between the change of serum levels of TGF-beta post vaccination and HER2 ICD vaccine-induced T cell responses. We found that the greater the magnitude of the HER2 specific T cell response, as demonstrated by IFN-gamma secretion, the greater the decrease in serum TGF-beta (p=0.0045, r=0.742). The correlation between the increased epitope spreading T cell response and decreased levels of TGF-beta was even more significant (p=0.0003). The median overall survival has not been reached with 100% of patients alive at this time. Relapse free survival data will be presented.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 5102.
Collapse
Affiliation(s)
| | - Y. Dang
- 1University of Washington, WA,
| | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Bates N, Higgins D, Childs J, Boettcher M, Salazar L, Disis M. The Impact of National Press Coverage on Early Phase Clinical Trial Recruitment and Enrollment. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-6078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The American Society of Clinical Oncologists reports that only 5% of cancer patients ultimately enroll in a clinical trial. According to the National Cancer Institute, one key barrier to participation is a lack of knowledge about clinical trials, both on behalf of oncologists and the patients themselves. Unfortunately, many investigator-initiated and academic clinical trials simply do not have budgets that permit implementation of large-scale recruitment efforts. Recent experience by our group demonstrates that press coverage by national media is a particularly effective tool for generating public interest in clinical research, as well as increasing trial enrollment.In the third quarter of 2008, our academic translational research group was featured on a national news program. In the week following the broadcast, our group's website, which had been listed in the broadcast and accompanying web story, received an unprecedented number of hits. Not only did the broadcast generate interest in our group's research; more specifically, it translated to substantial increases in potential clinical trial candidates, and subsequently, increased trial enrollment. In the month following the broadcast, our group received 125 new clinical trial inquiries as a result of the feature. That number represented a seven-fold increase in new inquiries during the same period in 2007. Of those 125 contacts, more than half of patients were potentially eligible for one of our clinical trials based on an initial screening. From November 2008 to the present, nearly one-third of all clinical trial enrollments can be attributed to the news story. Enrollment to the vaccine trial specifically described in the news feature increased four fold in comparison to the same 6-month period in 2008-2009, with half of all new enrollments attributable to the news feature.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 6078.
Collapse
|
48
|
Salazar LG, Wallace D, Mukherjee P, Higgins D, Childs J, Bates N, Coveler AL, Disis ML. HER2/neu (HER2) specific T-cell immunity in patients with HER2+ inflammatory breast cancer (IBC) and prognosis. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.3057] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3057 Background: IBC is rare, highly aggressive, and associated with worse prognosis when compared to non-IBC tumors. Moreover, multimodality treatment has had little impact on overall prognosis. HER2 is overexpressed in about 40% of IBC tumors and is associated with worse overall survival (OS). We have developed vaccines that elicit both HER2-specific CD4+ and CD8+ T-cell immunity in HER2+ cancer patients. Generation of HER2-specific T-cell immunity could (1) target immunogenic and biologically relevant proteins such as HER2 in IBC, (2) result in immunogenic eradication of HER2+ tumor cells, and (3) potentially prevent disease relapse when used in the adjuvant setting after standard therapy. A retrospective analysis of IBC patients immunized with HER2 vaccines was conducted to better understand the development of HER2-specific T-cell immunity and its possible impact on overall prognosis in IBC. Methods: Clinical and immunological data of IBC patients enrolled in University of Washington IRB approved HER2 vaccine trials was collected and reviewed. 27 patients immunized between 1996–2008 were identified; and 24/27 subjects who received vaccines designed to elicit both CD4+/CD8+ immunity were included in immunologic and survival analysis. The 24 subjects received either a HER2 DNA or HER2 peptide-based vaccine that were admixed with GM-CSF and given intradermally monthly for a total of 3 DNA or 6 peptide vaccines. Immune responses were assessed via IFN-γ ELISPOT at baseline and post-vaccination. Results: All 24 subjects had stage III IBC and median age was 48 (range 34–77). 10/24 (42%) patients had ER/PR+ tumors, 9/24 (37%) had received trastuzumab, and 15/24 (62%) had received multimodality treatment (chemotherapy, mastectomy, radiotherapy). 12/18 subjects (66%) evaluable for immunologic response developed HER2-specific T-cell immunity post-vaccination. Median OS for patients (n=6) not generating HER2-specific immunity was 31 months and median OS for the 12 patients who developed HER2-specific immunity has not been reached at median follow-up of 46 months, (p=0.026). Conclusions: Patients with IBC are able to generate HER2-specific T-cell immunity after HER2 vaccination, and development of HER2-specific immunity may impact survival. No significant financial relationships to disclose.
Collapse
Affiliation(s)
| | | | | | | | - J. Childs
- University of Washington, Seattle, WA
| | - N. Bates
- University of Washington, Seattle, WA
| | | | | |
Collapse
|
49
|
Salazar LG, Slota M, Wallace D, Higgins D, Coveler AL, Dang Y, Childs J, Bates N, Waisman J, Disis ML. A phase I study of a DNA plasmid based vaccine encoding the HER2/neu (HER2) intracellular domain (ICD) in subjects with HER2+ breast cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.3054] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3054 Background: HER2 is overexpressed in 25% of breast cancers and plays a role in the malignant transformation of cells. Vaccine-induced immunity against the HER2 ICD correlates with antitumor responses in animal models. DNA-based vaccines offer a strategy to immunize against multiple tumor antigens and are able to elicit both CTL and T helper immune responses. Plasmid DNA can also remain at the vaccine site, providing a constant source of antigen. However, DNA vaccines have been poorly immunogenic due in part to inefficient APC transfection. Intradermal (i.d.) delivery of DNA vaccines with GM-CSF as adjuvant may enhance immunogenicity due to local influx of dermal Langerhans cells. A phase I study was conducted to evaluate the safety and immunogenicity of a DNA-based vaccine encoding the HER2 ICD. Methods: 44 subjects with stage III and IV HER2+ breast cancer in complete remission were enrolled sequentially into 2 vaccine arms (22 subjects/arm) and received 10μg pNGVL3-hICD (Arm 1) or 100μg pNGVL3-hICD (Arm 2). All vaccines were admixed with 100μg GM-CSF and given i.d. monthly for a total of 3 vaccines. Toxicity was assessed at baseline, during vaccination, and at follow-up. Immune responses were assessed with IFN-γ ELISPOT at baseline and post-vaccination. Vaccine site biopsies were analyzed for plasmid persistence via RT-PCR, 1 and 6 months after vaccination. Results: 43 subjects (21 in Arm 1; 22 in Arm 2) completed 3 vaccines. Vaccine-related toxicity in both arms was primarily grade I/II; no cardiac or grade IV toxicity was observed. 13/21 (62%) subjects in Arm 1 developed T-cell immunity, defined as HER2-specific T cell precursors:PBMC, to the HER2 protein (median 1:5,972, range 1:717–1:3,000,000) and to p776, a HER2 pan DR binding epitope (median 1:3,150, range 1:543–1:108,696). 13/19 (68%) subjects in Arm 1 had persistent plasmid DNA at the vaccine site. ELISPOT and RT-PCR analysis for Arm 2 are on-going. Conclusions: Immunization with a DNA plasmid-based HER2 vaccine is safe and immunogenic. Moreover, plasmid DNA persists at the vaccine site post-immunization and HER2+ cancer patients are able to develop immunity to the HER2 ICD. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- L. G. Salazar
- University of Washington, Seattle, WA; Breastlink Medical Group, Inc., Long Beach, WA
| | - M. Slota
- University of Washington, Seattle, WA; Breastlink Medical Group, Inc., Long Beach, WA
| | - D. Wallace
- University of Washington, Seattle, WA; Breastlink Medical Group, Inc., Long Beach, WA
| | - D. Higgins
- University of Washington, Seattle, WA; Breastlink Medical Group, Inc., Long Beach, WA
| | - A. L. Coveler
- University of Washington, Seattle, WA; Breastlink Medical Group, Inc., Long Beach, WA
| | - Y. Dang
- University of Washington, Seattle, WA; Breastlink Medical Group, Inc., Long Beach, WA
| | - J. Childs
- University of Washington, Seattle, WA; Breastlink Medical Group, Inc., Long Beach, WA
| | - N. Bates
- University of Washington, Seattle, WA; Breastlink Medical Group, Inc., Long Beach, WA
| | - J. Waisman
- University of Washington, Seattle, WA; Breastlink Medical Group, Inc., Long Beach, WA
| | - M. L. Disis
- University of Washington, Seattle, WA; Breastlink Medical Group, Inc., Long Beach, WA
| |
Collapse
|
50
|
Disis ML, Salazar LG, Coveler A, Waisman J, Higgins D, Childs J, Bates N, Dang Y. Phase I study of infusion of HER2/neu (HER2) specific T cells in patients with advanced-stage HER2 overexpressing cancers who have received a HER2 vaccine. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.3000] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3000 Background: Adoptive T-cell therapy has shown promise in the treatment of advanced-stage melanoma. We have previously reported that expansion of HER2-specific T cells from peripheral blood mononuclear cells (PBMC) can be greatly facilitated by vaccine-priming. In this study, we evaluated the safety and clinical efficacy of infusion of HER2-specific T cells in patients with advanced HER2 overexpressing cancers. Methods: 10 patients with progressive HER2+ metastatic breast and ovarian cancer, not considered curable by conventional therapies, will be enrolled in this study. The patients must have been pre-immunized with a HER2-specific vaccine. Three escalating doses of T cells are given at 10-day intervals. Cyclophosphamide or denileukin diftitox is administrated before the first dose of T cells. Results: To date, 5 of 10 subjects have been enrolled. T cells were expanded with HER2-specific class II restricted peptides. After in vitro expansion cell products were >95% CD3+ with an average of 35% CD4+ and 60% CD8+ T cells. The maximal doses infused were 1x109-41x109 cells (median 10x109). Subjects tolerated the infusions well with the primary toxicity being related to the conditioning agent. Objective tumor regression has been observed in 2 of the 5 treated patients. One other patient has had stable disease after treatment. In patients with tumor regression, the magnitude of HER2-specific T cells in the infused product was 8-fold higher than that in patients without clinical responses. The total number of HER2-specific T cells infused was 43-fold higher in responding patients than in nonresponding patients. Moreover, HER2-specific CD4+ and CD8+ T cells persisted over a year and even augmented in magnitude post-infusion in responding patients. Conclusions: Adoptive transfer of autologous HER2 specific polyclonal T cells generated from PBMC after vaccine-priming is well tolerated and has shown evidence of some clinical efficacy in patients with advanced-stage HER2+ cancers. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. L. Disis
- University of Washington, Seattle, WA; Breastlink, Los Angeles, CA
| | - L. G. Salazar
- University of Washington, Seattle, WA; Breastlink, Los Angeles, CA
| | - A. Coveler
- University of Washington, Seattle, WA; Breastlink, Los Angeles, CA
| | - J. Waisman
- University of Washington, Seattle, WA; Breastlink, Los Angeles, CA
| | - D. Higgins
- University of Washington, Seattle, WA; Breastlink, Los Angeles, CA
| | - J. Childs
- University of Washington, Seattle, WA; Breastlink, Los Angeles, CA
| | - N. Bates
- University of Washington, Seattle, WA; Breastlink, Los Angeles, CA
| | - Y. Dang
- University of Washington, Seattle, WA; Breastlink, Los Angeles, CA
| |
Collapse
|